Analysts have been eager to weigh in on the Healthcare sector with new ratings on Creative Medical Technology Holdings (CELZ – Research Report), Boston Scientific (BSX – Research Report) and RenovoRx (RNXT – Research Report).
Creative Medical Technology Holdings (CELZ)
In a report issued on June 12, Jonathan Aschoff from Roth MKM maintained a Buy rating on Creative Medical Technology Holdings, with a price target of $30.00. The company’s shares closed last Friday at $4.92, close to its 52-week low of $3.30.
According to TipRanks.com, Aschoff is ranked #8423 out of 8514 analysts.
Currently, the analyst consensus on Creative Medical Technology Holdings is a Moderate Buy with an average price target of $30.00.
See Insiders’ Hot Stocks on TipRanks >>
Boston Scientific (BSX)
Credit Suisse analyst Lorenzo Biasio downgraded Boston Scientific to Hold on May 5 and set a price target of $54.00. The company’s shares closed last Friday at $53.03, close to its 52-week high of $54.75.
According to TipRanks.com, Biasio is a 4-star analyst with an average return of
Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $58.65, implying an 11.1% upside from current levels. In a report issued on April 27, Deutsche Bank also maintained a Hold rating on the stock with a $55.00 price target.
RenovoRx (RNXT)
Roth MKM analyst Scott Henry maintained a Buy rating on RenovoRx on June 13 and set a price target of $14.00. The company’s shares closed last Friday at $2.15, close to its 52-week low of $1.50.
According to TipRanks.com, Henry is a 3-star analyst with an average return of
RenovoRx has an analyst consensus of Moderate Buy, with a price target consensus of $11.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CELZ:
